GSK PLC - London-based pharmaceuticals firm - Says Dreamm-7 trial shows sustained overall survival benefit for Blenrep, the brand name of belantamab mafodotin, combination versus a daratumumab combination. The data build on findings from Dreamm-7 and Dreamm-8 and supports the potential for Blenrep combinations to become standard of care. Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse, company says.
Hesham Abdullah, senior vice president, Global Head Oncology, R&D, GSK, says: "The compelling overall survival data from the Dreamm-7 trial establish the potential of Blenrep in combination to significantly extend the lives of patients with multiple myeloma at or after first relapse. This represents an important advancement that could redefine the treatment of relapsed or refractory multiple myeloma."
Blenrep combinations are under regulatory review in seven major markets. Earlier Thursday, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer.
Current share price: 1,385.50 pence, up 3.1% in London on Monday
12-month change: down 4.3%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Glaxosmithkline (GSK)
